skip to Main Content


01 - 03 March

Geneva, Switzerland

Dear Colleagues,

We would like to cordially invite you to the third EASL Hepatocellular Carcinoma (HCC) Summit: From basic to clinical research: How to improve HCC clinical care? to be held in Geneva, Switzerland from 1-3 March 2018.

HCC is considered one of the most important causes of death in patients affected with chronic liver disease. In the past years, major advances in the early diagnosis and treatment, particularly in advanced stages, have taken place.

This Summit will cover both the basic and translational/clinical aspects of the disease, with a specific focus on new targeted therapies in HCC. Great efforts have been made in the scientific programme to enhance the interaction among basic scientists, clinical researchers, and Industry leaders to stimulate our combined efforts in addressing the key challenges in HCC.

This year’s programme will be informative and stimulating, covering a broad range of topics presented as high-quality presentations by renowned experts. We anticipate that this combination of high quality and interactive presentations by leading scientists and clinicians from academia and industry will be successful, and will help to move the field forward.

We are eager to welcome you in Geneva for this major event.


The Scientific Committee

Why attend?
  • 3 days of cutting edge basic and clinical research on liver cancer
  • Latest in clinical care and patient management
  • Showcase your research, gather and network with renowned scientists and leading experts
Who should attend?
  • Hepatologists
  • Physicians with interest in liver cancer
  • Young researchers and trainees
  • Basic and translational scientists
  • Clinical researchers
  • Health professionals
  • Industry